Advertisement

Annals of Surgical Oncology

, Volume 22, Issue 2, pp 505–512 | Cite as

Survival Paradox Between Stage IIB/C (T4N0) and Stage IIIA (T1-2N1) Colon Cancer

  • Min Jung Kim
  • Seung-Yong JeongEmail author
  • Sang-ji Choi
  • Seung-Bum Ryoo
  • Ji Won Park
  • Kyu Joo Park
  • Jae Hwan Oh
  • Sung-Bum Kang
  • Hyoung-Chul Park
  • Seung Chul Heo
  • Jae-Gahb Park
Colorectal Cancer

Abstract

Background

The survival paradox between stage IIB/C (T4N0) and stage IIIA (T1-2N1) colon cancer remains in the 7th edition of the American Joint Committee on Cancer staging system. This multicenter study aimed to compare the oncologic outcomes of T4N0 and T1-2N1 colon cancers and to investigate the presumptive prognostic factors that might influence the survival paradox.

Methods

Patients who underwent curative surgery for pT4N0 (n = 224) and pT1-2N1 (n = 135) primary colon cancer between January 1999 and December 2010 at five tertiary referral cancer centers were included for analysis. The clinicopathologic, treatment-related factors, and oncologic outcomes in terms of the 5-year overall survival (5-OS) and 5-year disease-free survival (5-DFS) were compared.

Results

The T4N0 group had significantly worse 5-OS and 5-DFS rates than the T1-2N1 group (5-OS: 84.0 vs. 92.3 %, p = 0.012; 5-DFS: 73.6 vs. 88.0 %, p = 0.001). T4N0 cancers more frequently showed elevated preoperative carcinoembryonic antigen, lower grade of differentiation, larger tumor size, and higher proportions of perineural invasion, microsatellite instability, obstruction, and perforation than T1-2N1 cancers. Peritoneal seeding and liver metastasis were the predominant recurrence pattern in the T4N0 and T1-2N1 groups, respectively (p = 0.042). The T4N0 group showed inferior survival to the T1-2N1 group in postoperative adjuvant chemotherapy (5-OS: 87.1 vs. 93.2 %, p = 0.045; 5-DFS: 76.1 vs. 89.0 %, p = 0.001).

Conclusions

T4N0 colon cancer had significantly worse oncologic outcomes than T1-2N1 cancer regardless of adjuvant chemotherapy. The survival paradox may result from the biologic aggressiveness of T4N0 colon carcinomas.

Keywords

Adjuvant Chemotherapy Oncologic Outcome T4N0 Tumor Colon Carcinoma Patient Tertiary Referral Cancer Center 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Conflict of interest

The authors declare there are no conflicts of interest or financial ties to disclose.

Supplementary material

10434_2014_3982_MOESM1_ESM.docx (12 kb)
Supplementary material 1 (DOCX 12 kb)
10434_2014_3982_MOESM2_ESM.docx (14 kb)
Supplementary material 2 (DOCX 13 kb)

References

  1. 1.
    O’Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2004;96(19):1420-5.CrossRefPubMedGoogle Scholar
  2. 2.
    Quirke P, Williams GT, Ectors N, Ensari A, Piard F, Nagtegaal I. The future of the TNM staging system in colorectal cancer: time for a debate? Lancet Oncol. 2007;8(7):651-7.CrossRefPubMedGoogle Scholar
  3. 3.
    Gunderson LL, Jessup JM, Sargent DJ, Greene FL, Stewart AK. Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010;28(2):264-71.PubMedCentralCrossRefPubMedGoogle Scholar
  4. 4.
    Lorenzon L, Pilozzi E, La Torre M, Ziparo V, Ferri M. Impact and prognostic implications of colon cancers stage II sub-classification through the years. Int J Colorectal Dis. 2012;27(10):1311-8.CrossRefPubMedGoogle Scholar
  5. 5.
    Hashiguchi Y, Hase K, Kotake K, et al. Evaluation of the seventh edition of the tumour, node, metastasis (TNM) classification for colon cancer in two nationwide registries of the United States and Japan. Colorectal Dis. 2012;14(9):1065-74.CrossRefPubMedGoogle Scholar
  6. 6.
    Jeong SY, Chessin DB, Schrag D, Riedel E, Wong WD, Guillem JG. Re: colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2005;97(22):1705-6; author reply 1706-7.CrossRefPubMedGoogle Scholar
  7. 7.
    Morris M, Platell C, de Boer B, McCaul K, Iacopetta B. Population-based study of prognostic factors in stage II colonic cancer. Br J Surg. 2006;93(7):866-71.CrossRefPubMedGoogle Scholar
  8. 8.
    Merkel S, Wein A, Gunther K, Papadopoulos T, Hohenberger W, Hermanek P. High-risk groups of patients with Stage II colon carcinoma. Cancer. 2001;92(6):1435-43.CrossRefPubMedGoogle Scholar
  9. 9.
    McKenzie S, Nelson R, Mailey B, et al. Adjuvant chemotherapy improves survival in patients with American Joint Committee on Cancer stage II colon cancer. Cancer. 2011;117(24):5493-9.CrossRefPubMedGoogle Scholar
  10. 10.
    Engstrom PF, Arnoletti JP, Benson AB 3rd, et al. NCCN clinical practice guidelines in oncology: colon cancer. J Natl Compr Cancer Netw. 2009;7(8):778–831.Google Scholar
  11. 11.
    Rottoli M, Stocchi L, Dietz DW. T4N0 colon cancer has oncologic outcomes comparable to stage III in a specialized center. Ann Surg Oncol. 2012;19(8):2500-5.CrossRefPubMedGoogle Scholar
  12. 12.
    Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998;58(22):5248-57.PubMedGoogle Scholar
  13. 13.
    Benson AB 3rd, Schrag D, Somerfield MR, et al. American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22(16):3408-19.CrossRefPubMedGoogle Scholar
  14. 14.
    Law CH, Wright FC, Rapanos T, et al. Impact of lymph node retrieval and pathological ultra-staging on the prognosis of stage II colon cancer. J Surg Oncol. 2003;84(3):120-6.CrossRefPubMedGoogle Scholar
  15. 15.
    Joseph NE, Sigurdson ER, Hanlon AL, et al. Accuracy of determining nodal negativity in colorectal cancer on the basis of the number of nodes retrieved on resection. Ann Surg Oncol. 2003;10(3):213-8.CrossRefPubMedGoogle Scholar
  16. 16.
    Wong JH, Severino R, Honnebier MB, Tom P, Namiki TS. Number of nodes examined and staging accuracy in colorectal carcinoma. J Clin Oncol. 1999;17(9):2896-900.PubMedGoogle Scholar
  17. 17.
    Matsuda T, Saito Y, Fujii T, et al. Size does not determine the grade of malignancy of early invasive colorectal cancer. World J Gastroenterol. 2009;15(22):2708-13.PubMedCentralCrossRefPubMedGoogle Scholar
  18. 18.
    Poritz LS, Sehgal R, Hartnett K, Berg A, Koltun WA. Tumor volume and percent positive lymph nodes as a predictor of 5-year survival in colorectal cancer. Surgery. 2011;150(4):649-55.CrossRefPubMedGoogle Scholar
  19. 19.
    Benedix F, Meyer F, Kube R, et al. Influence of anatomical subsite on the incidence of microsatellite instability, and KRAS and BRAF mutation rates in patients with colon carcinoma. Pathol Res Pract. 2012;208(10):592-7.CrossRefPubMedGoogle Scholar
  20. 20.
    Maak M, Simon I, Nitsche U, et al. Independent validation of a prognostic genomic signature (coloprint) for patients with stage ii colon cancer. Ann Surg. 2013;257(6):1053-8.CrossRefPubMedGoogle Scholar
  21. 21.
    Webber EM, Lin JS, Evelyn PW. Oncotype DX tumor gene expression profiling in stage II colon cancer. Application: prognostic, risk prediction. PLoS Curr. 2010;2.Google Scholar

Copyright information

© Society of Surgical Oncology 2014

Authors and Affiliations

  • Min Jung Kim
    • 1
  • Seung-Yong Jeong
    • 2
    • 3
    • 4
    Email author
  • Sang-ji Choi
    • 2
  • Seung-Bum Ryoo
    • 2
  • Ji Won Park
    • 2
    • 3
    • 4
  • Kyu Joo Park
    • 2
    • 4
  • Jae Hwan Oh
    • 1
  • Sung-Bum Kang
    • 2
    • 5
  • Hyoung-Chul Park
    • 6
  • Seung Chul Heo
    • 2
    • 7
  • Jae-Gahb Park
    • 1
    • 3
  1. 1.Center for Colorectal CancerNational Cancer CenterGoyangKorea
  2. 2.Department of SurgerySeoul National University College of MedicineSeoulKorea
  3. 3.Cancer Research InstituteSeoul National UniversitySeoulKorea
  4. 4.Colorectal Cancer CenterSeoul National University Cancer HospitalSeoulKorea
  5. 5.Department of SurgerySeoul National University Bundang HospitalSeongnamKorea
  6. 6.Department of SurgeryHallym University College of MedicineAnyangKorea
  7. 7.Department of SurgerySeoul Metropolitan Government-Seoul National University Boramae Medical CenterSeoulKorea

Personalised recommendations